Excalipoint closes $68.7M seed round for cancer T-cell engagers
Excalipoint Therapeutics Inc. launched with an oversubscribed $68.7 million seed financing round to advance a portfolio of T-cell engagers for solid tumors, marking one of the largest early stage financings in China biotech history.
MC
marian chu
via Bioworld
Updated 18h ago

Source Verification
Corroboration Score: 1This story was independently reported by 1 sources. Click any source to read the original article.
Comments
0 commentsBe respectful and constructive.
Loading comments...
Previous
Eurosets Launches U.S. Commercialization of Trilly and Horizon Following FDA Clearance and Enters Strategic Partnership with Orion Medical
Next
Heart benefits fade after stopping GLP-1 medications
Related Articles
Science【AICC Original Article】Appreciating the Grand Canal through Rows of Willows: A Time-honored Cultural Pulse Reinvigorated
Unknown-5h ago-1 sources
One Dead, Three Trapped After Kericho Building Collapses
Unknown-9h ago-1 sources
ScienceHow AI-generated videos are distorting your child’s YouTube feed
Merinvarghese-10h ago-1 sources